Company & Sponsor Intelligence

Amgen

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials4

Recruiting2

Completed2

Countries2

Therapeutic footprint

depressionmigraine_headachemultiple_sclerosis

Indexed studies

NCT06180278Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
multiple_sclerosis · United StatesPHASE4

NCT03927144Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
migraine_headache · United StatesPHASE4

NCT03284879Post-Marketing Surveillance Study of OTEZLA
depression · JapanCOMPLETED

NCT05549258Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
multiple_sclerosis · United StatesPHASE2

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →